The C4A and C4B Isotypic Forms of Human Complement Fragment C4b Have the Same Intrinsic Affinity for Complement Receptor 1 (CR1/CD35)

Journal of Immunology

Volumn 172, Issue 3, 2004, Pages 1670-1680

  Clemenza, Liliana ^a,b   Isenman, David E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT RECEPTOR; DIMER; DISULFIDE; MONOMER; OLIGOMER;

ARTICLE; BIOSENSOR; CHROMATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; SURFACE PLASMON RESONANCE;

EID: 1642444068     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.3.1670     Document Type: Article

References (53)

1. Lay, W. H., and V. Nussenzweig. 1968. Receptors for complement of leukocytes. J. Exp. Med. 128:991.
2. Cooper, N. R. 1969. Immune adherence by the fourth component of complement. Science 165:396.
3. Klickstein, L. B., W. W. Wong, J. A. Smith, J. H. Weis, J. G. Wilson, and D. T. Fearon. 1987. Human C3b/C4b receptor (CR1): demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4 binding proteins. J. Exp. Med. 165:1095.
4. Hourcade, D., D. R. Miesner, J. P. Atkinson, and V. M. Holers. 1988. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J. Exp. Med. 168:1255.
5. Klickstein, L. B., T. J. Bartow, V. Miletic, L. D. Rabson, J. A. Smith, and D. T. Fearon. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168:1699.
6. Krych, M., D. Hourcade, and J. P. Atkinson. 1991. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc. Natl. Acad. Sci. USA 88:4353.
7. 2 chimeric complement inhibitor. J. Exp. Med. 174:1451.
8. Krych, M., R. Hauhart, and J. P. Atkinson. 1998. Structure-function analysis of the active sites of complement receptor type 1. J. Biol. Chem. 273:8623.
9. Reilly, B. D., S. C. Makrides, P. J. Ford, H. C. Marsh, Jr., and C. Mold. 1994. Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J. Biol. Chem. 269:7696.
10. Krych, M., L. Clemenza, D. Howdeshell, R. Hauhart, D. Hourcade, and J. P. Atkinson. 1994. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J. Biol. Chem. 269:13273.
11. Blanchong, C. A., E. K. Chung, K. L. Rupert, Y. Yang, Z. Yang, B. Zhou, J. M. Moulds, and C. Y. Yu. 2001. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int. Immunopharmacol. 1:365.
12. Yu, C. Y., R. D. Campbell, and R. R. Porter. 1988. A structural model for the location of the Rodgers and the Chido antigenic determinants and their correlation with the human complement component C4A/C4B isotypes. Immunogenetics 27:399.
13. Isenman, D. E., and J. R. Young. 1984. The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4. J. Immunol. 132:3019.
14. Law, S. K., A. W. Dodds, and R. R. Porter. 1984. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J. 3:1819.
15. Carroll, M. C., D. M. Fathallah, L. Bergamaschini, E. M. Alicot, and D. E. Isenman. 1990. Substitution of a single amino acid (aspartic acid for histidine) converts the functional activity of human complement C4B to C4A. Proc. Natl. Acad. Sci. USA 87:6868.
16. Sepp, A., A. W. Dodds, M. J. Anderson, R. D. Campbell, A. C. Willis, and S. K. Law. 1993. Covalent binding properties of the human complement protein C4 and hydrolysis rate of the internal thioester upon activation. Protein Sci. 2:706.
17. Dodds, A. W., X. D. Ren, A. C. Willis, and S. K. Law. 1996. The reaction mechanism of the internal thioester in the human complement component C4. Nature 379:177.
18. Law, S. K., and A. W. Dodds. 1997. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6:263.
19. Kishore, N., D. Shah, V. M. Skanes, and R. P. Levine. 1988. The fluid-phase binding of human C4 and its genetic variants, C4A3 and C4B1, to immunoglobulins. Mol. Immunol. 25:811.
20. Schifferli, J. A., and J. P. Paccaud. 1989. Two isotypes of human C4, C4A and C4B have different structure and function. Complement Inflamm. 6:19.
21. Paul, L., V. M. Skanes, J. Mayden, and R. P. Levine. 1988. C4-mediated inhibition of immune precipitation and differences in inhibitory action of genetic variants, C4A3 and C4B1. Complement 5:110.
22. Ebanks, R. O., A. S. Jaikaran, M. C. Carroll, M. J. Anderson, R. D. Campbell, and D. E. Isenman. 1992. A single arginine to tryptophan interchange at β-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6: implications for the location of a C5 binding site in C4. J. Immunol. 148:2803.
23. Gatenby, P. A., J. E. Barbosa, and P. J. Lachmann. 1990. Differences between C4A and C4B in the handling of immune complexes: the enhancement of CR1 binding is more important than the inhibition of immunoprecipitation. Clin. Exp. Immunol. 79:158.
24. Gibb, A. L., A. M. Freeman, R. A. Smith, S. Edmonds, and E. Sim. 1993. The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4. Biochim. Biophys. Acta 1180:313.
25. Reilly, B. D., and C. Mold. 1997. Quantitative analysis of C4Ab and C4Bb binding to the C3b/C4b receptor (CR1, CD35). Clin. Exp. Immunol. 110:310.
26. Pickering, M. C., M. Botto, P. R. Taylor, P. J. Lachmann, and M. J. Walport. 2001. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 76:227.
27. Schur, P. H., D. Marcus-Bagley, Z. Awdeh, E. J. Yunis, and C. A. Alper. 1990. The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum. 33:985.
28. Dragon-Durey, M. A., N. Rougier, J. P. Clauvel, S. Caillat-Zucman, P. Remy, L. Guillevin, F. Liote, J. Blouin, F. Ariey, B. U. Lambert, et al. 2001. Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4-deficient patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 123:133.
29. Atkinson, J. P. 1989. Complement deficiency: predisposing factor to autoimmune syndromes. Clin. Exp. Rheumatol. 7(Suppl. 3):S95.
30. Kemp, M. E., J. P. Atkinson, V. M. Skanes, R. P. Levine, and D. D. Chaplin. 1987. Deletion of C4A genes in patients with systemic lupus erythematosus. Arthritis Rheum. 30:1015.
31. Howard, P. F., M. C. Hochberg, W. B. Bias, F. C. Arnett, Jr., and R. H. McLean. 1986. Relationship between C4 null genes, HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasian and black Americans. Am. J. Med. 81:187.
32. Hartung, K., M. P. Baur, R. Coldewey, M. Fricke, J. R. Kalden, H. J. Lakomek, H. H. Peter, D. Schendel, P. M. Schneider, S. A. Seuchter, et al. 1992. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus: results of a multicenter study. J. Clin. Invest. 90:1346.
33. Olsen, M. L., R. Goldstein, F. C. Arnett, M. Duvic, M. Pollack, and J. D. Reveille. 1989. C4A gene deletion and HLA associations in black Americans with systemic lupus erythematosus. Immunogenetics 30:27.
34. Dunckley, H., P. A. Gatenby, B. Hawkins, S. Naito, and S. W. Serjeantson. 1987. Deficiency of C4A is a genetic determinant of systemic lupus erythematosus in three ethnic groups. J. Immunogenet. 14:209.
35. Fielder, A. H., M. J. Walport, J. R. Batchelor, R. I. Rynes, C. M. Black, I. A. Dodi, and G. R. Hughes. 1983. Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br. Med. J. (Clin. Res. Ed.) 286:425.
36. Kristjansdottir, H., K. Bjarnadottir, I. B. Hjalmarsdottir, G. Grondal, A. Arnason, and K. Steinsson. 2000. A study of C4AQ0 and MHC haplotypes in Icelandic multicase families with systemic lupus erythematosus. J. Rheumatol. 27:2590.
37. Man, X. Y., H. R. Luo, X. P. Li, Y. G. Yao, C. Z. Mao, and Y. P. Zhang. 2003. Polymerase chain reaction based C4AQ0 and C4BQ0 genotyping: association with systemic lupus erythematosus in southwest Han Chinese. Ann. Rheum. Dis. 62:71.
38. Prodeus, A. P., S. Goerg, L. M. Shen, O. O. Pozdnyakova, L. Chu, E. M. Alicot, C. C. Goodnow, and M. C. Carroll. 1998. A critical role for complement in maintenance of self-tolerance. Immunity 9:721.
39. Chen, Z., S. B. Koralov, and G. Kelsoe. 2000. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J. Exp. Med. 192:1339.
40. Van den Elsen, J. M., A. Martin, V. Wong, L. Clemenza, D. R. Rose, and D. E. Isenman. 2002. X-ray crystal structure of the C4d fragment of human complement component C4. J. Mol. Biol. 322:1103.
41. Tack, B. F., J. Janatova, M. L. Thomas, R. A. Harrison, and C. H. Hammer. 1981. The third, fourth, and fifth components of human complement: isolation and biochemical properties. Methods Enzymol. 80:64.
42. Janatova, J., and B. F. Tack. 1981. Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component. Biochemistry 20:2394.
43. Hessing, M., J. Paardekooper, and C. E. Hack. 1993. Separation of different forms of the fourth component of human complement by fast protein liquid chromatography. J. Immunol. Methods 157:39.
44. Nagasawa, S., C. Ichihara, and R. M. Stroud. 1980. Cleavage of C4b by C3b inactivator: production of a nicked form of C4b, C4b′, as an intermediate cleavage product of C4b by C3b inactivator. J. Immunol. 125:578.
45. Nagasawa, S., and R. M. Stroud. 1980. Purification and characterization of a macromolecular weight cofactor for C3b-inactivator, C4bC3blNA-cofactor, of human plasma. Mol. Immunol. 17:1365.
46. Feldman, H. A. 1972. Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting. Anal. Biochem. 48:317.
47. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, Jr., G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
48. Isenman, D. E., and J. R. Young. 1986. Covalent binding properties of the C4A and C4B isotypes of the fourth component of human complement on several C1-bearing cell surfaces. J. Immunol. 136:2542.
49. Paccaud, J. P., J. L. Carpentier, and J. A. Schifferli. 1990. Difference in the clustering of complement receptor type 1 (CR1) on polymorphonuclear leukocytes and erythrocytes: effect on immune adherence. Eur. J. Immunol. 20:283.
50. Becherer, J. D., and J. D. Lambris. 1988. Identification of the C3b receptor-binding domain in third component of complement. J. Biol. Chem. 263:14586.
51. Jokiranta, T. S., J. Westin, U. R. Nilsson, B. Nilsson, J. Hellwage, S. Lofas, D. L. Gordon, K. N. Ekdahl, and S. Meri. 2001. Complement C3b interactions studied with surface plasmon resonance technique. Int. Immunopharmacol. 1:495.
52. Smith, B. O., R. L. Mallin, M. Krych-Goldberg, X. Wang, R. E. Hauhart, K. Bromek, D. Uhrin, J. P. Atkinson, and P. N. Barlow. 2002. Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 108:769.
53. Blanchong, C. A., B. Zhou, K. L. Rupert, E. K. Chung, K. N. Jones, J. F. Sotos, W. B. Zipf, R. M. Rennebohm, and C. Yung Yu. 2000. Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in Caucasians: the load of RCCX genetic diversity on major histocompatibility complex-associated disease. J. Exp. Med. 191:2183.